ArticleScientific reports2025
Diagnostic accuracy of urinary PENK methylation test for urothelial and other cancers: A prospective study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Biological fit and clinical utility in upper tract urothelial carcinoma diagnostics: positioning Oncuria-Detect within an evidence-based, layered biomarker framework.Translational andrology and urology · 2026Article
- Diagnostic potential of urinaryTranslational andrology and urology · 2026Article
- Artificial intelligence and multi-omics integration in liquid biopsy for genitourinary cancers: a systematic scoping review.International urology and nephrology · 2026Article
- Article
- EarlyTect BCD Plus: A urine-based dual site PENK methylation test for risk-based cystoscopy triage in haematuria.BJUI compass · 2026Article
- Artificial Intelligence-Enabled Multi-Omics for Predicting Immune Checkpoint Inhibitor Response and Resistance.Journal of multidisciplinary healthcare · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The methylated PENK gene is known to be highly expressed in the urine of patients with bladder cancer. Recent large-scale multicenter studies have confirmed the robust diagnostic performance of urinary PENK methylation, reporting high sensitivity and specificity for bladder cancer detection. However, its association with other cancers remains unclear. This prospective study aimed to determine the diagnostic accuracy of the urinary PENK methylation test for urothelial carcinoma among patients with 13 different cancer types. Between August 2022 and April 2023, 183 patients were enrolled, including 17 with urothelial carcinoma (eight bladder cancer and nine upper tract urothelial carcinoma) and 166 with other cancers. The urinary PENK methylation test showed an overall sensitivity of 94.1% (87.5% for bladder cancer and 100% for UTUC) and a specificity of 95.8% when patients with non-urothelial cancers were used as the control group. Positive urinary PENK methylation test was obtained for two patients with cervical cancer (25.0%), 2 with colorectal cancer (10.5%), and one patient each with esophageal (4.8%), liver (5.0%), and kidney (5.3%) cancer. These findings confirm the high sensitivity and specificity of the urinary PENK methylation test for detecting urothelial carcinoma and support its potential as a non-invasive biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.